A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Completed · Phase 3 · Has a placebo group

Conditions studied: Irritable Bowel Syndrome With Constipation (IBS-C)

In brief

This clinical trial is an international, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial comparing one dose of linaclotide to placebo. Approximately 800 patients with a diagnosis of IBS-C (modified Rome III criteria) will be randomized at up to 60 trial centers in China, Australia, and New Zealand. The trial will consist of up to 21 days of screening, 14 to 21 days of pre-treatment, 12 weeks of double-blind treatment, and 2 weeks of follow-up. At the end of the Pre-treatment Period, patients meeting the entry criteria for this trial will be randomized to one of two double-blind treatment groups: 290 ug linaclotide, or placebo (1:1).

Key facts

Study ID

NCT01880424

Run by

AstraZeneca

People needed

1722

Starts

2013-07-01

Expected to finish

2015-05-01

Last updated by the study team

2016-09-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient has signed an Informed Consent Form(ICF).
• Patient Must not be pregnant or breastfeeding and agree to use birth control
• Patient meets the colonoscopy requirements defined by the American Gastroenterological Association guidelines and no clinically-significant laboratory or physical examination findings;
• Patient meets protocol-defined criteria for Irritable Bowel Syndrome with Constipation(IBS-C), including stool frequency, straining, stool consistency, abdominal pain, and abdominal discomfort criteria
• Patient meets protocol-defined eDiary completion Compliance and agrees to refrain from making any new, major life-style changes that may affect IBS-C symptoms

You may not qualify if…

• Recent history of mushy or watery stools
• Various medical conditions, medical histories, or family medical histories that would not make the patient a good candidate for the study
• Patient currently has both unexplained and clinically significant alarm symptoms or systemic signs of infection or colitis.
• Surgery to the gastrointestinal tract
• Usage of prohibited medications

Where it is running

• Research Site — North Little Rock, Arkansas, United States
• Research Site — Phoenix, Arkansas, United States
• Research Site — Artesia, California, United States
• Research Site — Chula Vista, California, United States
• Research Site — Encino, California, United States
• Research Site — North Hollywood, California, United States
• Research Site — Orange, California, United States
• Research Site — Riverside, California, United States
• Research Site — San Diego, California, United States
• Research Site — Boynton Beach, Florida, United States
• Research Site — Brandon, Florida, United States
• Research Site — Brooksville, Florida, United States
• Research Site — Doral, Florida, United States
• Research Site — Gainesville, Florida, United States
• Research Site — Hialeah, Florida, United States
• Research Site — Kissimmee, Florida, United States
• Research Site — Lauderdale Lakes, Florida, United States
• Research Site — Miami, Florida, United States
• Research Site — Miami Lakes, Florida, United States
• Research Site — Addison, Illinois, United States
• Research Site — Evansville, Indiana, United States
• Research Site — Crowley, Louisiana, United States
• Research Site — Monroe, Louisiana, United States
• Research Site — Shreveport, Louisiana, United States
• Research Site — Huntsville, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.